HCPCS J0480: Basiliximab Injection, 20 mg

HCPCS Level II code J0480 denotes a 20 mg injection of basiliximab, a monoclonal antibody used primarily to prevent acute rejection in organ transplant recipients. This code captures administration of a biologic immunosuppressive agent typically given in hospital outpatient infusion centers or during inpatient transplant stays. Nationally, basiliximab is a clinically important agent in transplant protocols and is subject to payer coverage policies and site-of-care considerations that affect access and billing.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for basiliximab use, payer coverage frameworks, and benchmarking elements typically examined in reimbursement analyses. The publication outlines expected service settings, common billing considerations for an injectable biologic, and where to look for policy updates affecting prior authorization and coverage criteria.

This summary provides an overview of what to expect when coding and billing HCPCS Level II code J0480: clinical indication and administration context, payer coverage landscape, and topics typically included in benchmarking and policy update sections. Data not available in the input will be noted where applicable in the full publication.

Billing Code Overview

HCPCS Level II code J0480 represents an injection of basiliximab, 20 mg. This service is a monoclonal antibody immunosuppressive therapy typically administered intravenously for prevention of acute organ transplant rejection. The service type is injectable biologic therapy, and the typical site of service is hospital outpatient infusion center or inpatient hospital setting.

Data not available in the input.

Clinical Context

A typical patient is a 45–60-year-old adult undergoing kidney transplantation who receives J0480 (injection, basiliximab, 20 mg) as part of perioperative immunosuppressive induction therapy. The clinical workflow begins in the preoperative evaluation where the transplant surgeon and transplant nephrologist determine induction needs. On the day of transplant, pharmacy prepares J0480 dose(s) per protocol; the first dose is administered intravenously in the operating room or immediate post-anesthesia care unit prior to graft reperfusion or within the first hours after reperfusion, and a second dose is commonly given on postoperative day 4. Vital signs and infusion site are monitored by nursing staff; medication administration is documented in the electronic medical record with lot number and injector. Typical sites of service include the hospital inpatient setting, operating room, post-anesthesia care unit, and hospital outpatient infusion center for any subsequent dose administration. Common clinical indications include prophylaxis against acute organ rejection in solid organ transplantation (most often kidney transplant) in patients with low to moderate immunologic risk.

Coding Specifications

Modifier	Description	When to Use
`00`	Service/Procedure Complete — No Unusual Event	Rarely used; indicates standard completion when required by payer.

Taxonomy Code	Specialty	Notes
`2080S0004X`	Transplant Surgery	Surgeons who perform solid organ transplants and oversee perioperative therapies.
`207RP0000X`	Nephrology	Transplant nephrologists who manage immunosuppression protocols.
`208D00000X`	General Surgery	Surgeons involved in abdominal organ transplantation in some centers.
`363L00000X`	Clinical Pharmacology	Pharmacists specialized in transplant medication management and dosing.
`163W00000X`	Critical Care Medicine	Intensivists involved in perioperative care for complex transplant patients.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`T86.10`	Unspecified complication of kidney transplant	Represents post-transplant complications where induction immunosuppression with `J0480` may be relevant.
`T86.11`	Rejection of kidney transplant	Acute rejection prevention and treatment context; basiliximab is used for prophylaxis against acute rejection.
`Z94.0`	Kidney transplant status	Identifies a patient as a kidney transplant recipient who may receive induction agents like `J0480`.
`Z48.21`	Encounter for aftercare following kidney transplant	Postoperative visits where immunosuppressive regimen including `J0480` dosing is documented.
`N18.9`	Chronic kidney disease, unspecified	End-stage renal disease or advanced CKD is the typical indication leading to transplantation and use of `J0480`.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99223`	Initial hospital care, typically 70 minutes or more, for the evaluation and management of a patient, usually the admitting physician	Preoperative evaluation and inpatient E/M documentation for transplant recipients who will receive `J0480`.
`00540`	Anesthesia for kidney transplantation	Anesthesia services billed for operative period when `J0480` is administered intraoperatively.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if institutional policy requires an administration code for non-IV injectable medications when applicable; for IV infusion administrations another administration method code may be used.
`36415`	Collection of venous blood by venipuncture	Routine laboratory draws for baseline and post-transplant monitoring associated with immunosuppressive therapy.
`36561`	Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump, age 5 years or older	Access procedures that may be performed to facilitate repeated intravenous administrations including induction medications when peripheral access is inadequate.

OpenPayer

Summary & Overview